Efficient Anti-Tumor Immunotherapy Using Tumor Epitope-Coated Biodegradable Nanoparticles Combined With Polyinosinic-Polycytidylic Acid and an Anti-PD1 Monoclonal Antibody
Open Access
- 25 October 2022
- journal article
- research article
- Published by XMLink in Immune Network
- Vol. 22 (5) , e42
Abstract
Kim SH, et al. Immune Netw. 2022 Oct;22(5):e42. https://doi.org/10.4110/in.2022.22.e42Keywords
All Related Versions
Funding Information
- National Research Foundation of Korea (NRF-2020R1A2C1009484, MRC-2017R1A5A2015541)
This publication has 46 references indexed in Scilit:
- Adjuvants for peptide-based cancer vaccinesJournal for ImmunoTherapy of Cancer, 2016
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic MelanomaClinical Cancer Research, 2015
- Vaccine adjuvant uses of poly-IC and derivativesExpert Review of Vaccines, 2014
- Dipeptides promote folding and peptide binding of MHC class I moleculesProceedings of the National Academy of Sciences, 2013
- Molecular mechanisms of T cell co-stimulation and co-inhibitionNature Reviews Immunology, 2013
- BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responsesCancer Immunology, Immunotherapy, 2012
- TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancersCancer Immunology, Immunotherapy, 2012
- The Present and Future of Peptide Vaccines for CancerThe Cancer Journal, 2011
- Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responsesExpert Review of Vaccines, 2010
- APC-derived cytokines and T cell polarization in autoimmune inflammationJournal of Clinical Investigation, 2007